Aspen Pharmacare Holdings Limited
GPTKB entity
Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Sigma_Pharmaceuticals
GSK's_thrombosis_business |
| gptkbp:CEO |
gptkb:Stephen_Saad
|
| gptkbp:employees |
over 10,000
|
| gptkbp:focus |
Cardiology
Gastroenterology HIV/AIDS Immunology Oncology Pain management Research and development Supply chain management Transplantation Urology Women's health Clinical trials Diabetes Neurology Ophthalmology Quality assurance Anesthesia Infectious diseases Pediatrics Rheumatology Corporate social responsibility Endocrinology Hematology Vaccines Dermatology Regulatory affairs Sustainability initiatives Chronic diseases Market access Nutritional products Biologics Cardiovascular Respiratory Thrombosis Pharmacovigilance Men's health CNS Biosimilars Sales and marketing Anti-infectives Acute diseases Orphan_drugs |
| gptkbp:founded |
1850
|
| gptkbp:headquarters |
gptkb:South_Africa
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aspen Pharmacare Holdings Limited
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
Global
|
| gptkbp:partnerships |
gptkb:World_Health_Organization
|
| gptkbp:products |
Branded drugs
Generic_drugs |
| gptkbp:revenue |
$3.2 billion (2020)
|
| gptkbp:subsidiary |
Aspen_Global_Incorporated
Aspen_Pharmacare_Australia |